Skip to main content
Top of the Page

SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to expedite worldwide research and education through the exchange of scientific information.

Learn more »

SOHO represents physicians and other professionals from all corners of the world. SOHO is leading vital efforts to further treatments for those with hematologic malignancies.

Become a SOHO Member free-of-charge. Join us and experience the benefits of membership.

Join Now

The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. Note that SOHO members receive a 40% discount on registration fees. The twelfth annual meeting of the Society of Hematologic Oncology (SOHO 2024) is scheduled for September 4-7, 2024 at the GRB Convention Center in Houston, Texas. As a hybrid event, SOHO 2024 offers in-person, virtual and on-demand participation.

Register Now
  • 7,725 members strong

Join Us Today and Become a Part of the SOHO Community

Benefits of membership include:
  • Instant connections to our SOHO Community of more than 6,000 members
  • Access to a comprehensive Resource Center that includes slides, publications, abstracts, videos & more
  • Connection to our SOHO DocMatter Community for hematologic oncology discussions and education
  • Free online access to our official journal, ‘Clinical Lymphoma Myeloma and Leukemia
  • Free online and print subscription (US members) to our news publication, 'Blood Cancers Today'
  • Significant member-only discounts on meetings and events
  • Early member-only registration and housing opportunities
  • ... and much more!

Ambassador Program

The Ambassador Program was created to increase geographical diversity and promote international understanding among hematologic oncology experts around the world. If you are interested, Contact us!

Latest News

Selinexor Added to China’s National Reimbursement Drug List

Selinexor is an oral inhibitor for the treatment of relapsed or refractory multiple myeloma.

China’s NMPA Accepts sBLA for Relma-Cel Injection

In a clinical trial, relma-cel demonstrated a three-month ORR of 81.36% in patients with relapsed or refractory MCL.

Get to Know ... Ching-Hon Pui, MD

Dr. Pui, of St. Jude Children’s Research Hospital, discusses his lifelong commitment to being a pediatric oncologist.

FDA Grants Breakthrough Device Designation for Multicancer Early Detection Solution

CanScan uses low-depth whole-genome sequencing to detect early cancer signals with 99% specificity.

Foretinib Treatment Inhibits FLT3, Effective in AML Cell Lines

Foretinib also showed potent activity against secondary mutations that drive resistance to quizartinib and gilteritinib.

FDA Places Magrolimab Trials on Full Clinical Hold; AML ENHANCE-3 Trial Discontinued

Gilead said that it "will not pursue further development of magrolimab in hematologic cancers."

Application for Linvoseltamab in Multiple Myeloma Accepted for Review in Europe

The Marketing Authorization Application for linvoseltamab has been submitted and is under review by the EMA.

"Very interesting and exciting to share ideas and data with other hem/onc clinicians and scientists from around the world"
–Prof. Dieter Hoelzer, founding member
Back to Top